Lourens T Bloem

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 20

Top Topics

Transcription Factor

Drug Administration

Top Venues

Clinical pharmacology and therapeutics

BMJ (Clinical research ed.)

International journal of health policy and management

Expert opinion on drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
High cost oncology drugs without proof of added benefit are burdening health systems. BMJ (Clinical research ed.) 384 (2024)
Stefan Verweij, Vincent Haverhoek, Erik Bergman, Gabriel Westman, Lourens T Bloem
A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization Process. Clinical pharmacology and therapeutics 115 (4) (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
High cost oncology drugs without proof of added benefit are burdening health systems. BMJ (Clinical research ed.) 384 (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. BMJ (Clinical research ed.) 384 (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. BMJ (Clinical research ed.) 384 (2024)
Milad Sadreghaemy, Magdalena A Gamba, Lourens T Bloem, Antoine C G Egberts
Leftover of Amoxicillin Suspension After Use by Children in the Netherlands. Pharmacoepidemiology and drug safety 33 (8) (2024)
Stefan Verweij, Vincent Haverhoek, Erik Bergman, Gabriel Westman, Lourens T Bloem
A Natural Language Processing Approach towards Harmonized Communication of Uncertainties Identified during the European Medicine Authorization Process. Clinical pharmacology and therapeutics (2024)
Stefan Verweij, Vincent Haverhoek, Erik Bergman, Gabriel Westman, Lourens T Bloem
A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization Process. Clinical pharmacology and therapeutics 115 (4) (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. BMJ (Clinical research ed.) 384 (2024)
Jorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, Lourens T Bloem
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical pharmacology and therapeutics (2024)
Jorge Madrid Paredes, Jan-Willem Versteeg, Rick A Vreman, Lourens T Bloem
Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations. Clinical pharmacology and therapeutics 116 (1) (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
High cost oncology drugs without proof of added benefit are burdening health systems. BMJ (Clinical research ed.) 384 (2024)
Stefan Verweij, Vincent Haverhoek, Erik Bergman, Gabriel Westman, Lourens T Bloem
A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization Process. Clinical pharmacology and therapeutics 115 (4) (2024)
Francine Brinkhuis, Wim G Goettsch, Aukje K Mantel-Teeuwisse, Lourens T Bloem
Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study. BMJ (Clinical research ed.) 384 (2024)
Marjon V Verschueren, Talitha Dijs, Judith L Gulikers, Ard van Veelen, Sander Croes, Lizza E L Hendriks, Adrianus Aj Smit, Lourens T Bloem, Antoine C G Egberts, Ewoudt M W van de Garde, Bas Jm Peters
Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results. Immunotherapy (2023)
Lourens T Bloem, Jasmin Schelhaas, Lucía López-Anglada, Carla Herberts, Paula B van Hennik, Olli Tenhunen
European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006-2020. Clinical pharmacology and therapeutics (2023)
Lourens T Bloem, Jasmin Schelhaas, Lucía López-Anglada, Carla Herberts, Paula B van Hennik, Olli Tenhunen
European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006-2020. Clinical pharmacology and therapeutics (2023)
Lourens T Bloem, Rosalinde E Bot, Aukje K Mantel-Teeuwisse, Menno E van der Elst, Gabe S Sonke, Olaf H Klungel, Hubert G M Leufkens, Jarno Hoekman
Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: a comparison with standard approved cancer drugs. British journal of clinical pharmacology (2021)
Lourens T Bloem, Mariana Karomi, Jarno Hoekman, Menno E van der Elst, Hubert G M Leufkens, Olaf H Klungel, Aukje K Mantel-Teeuwisse
Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle - a focus on benefits and risks. Expert opinion on drug safety 20 (11) (2021)
Rick A Vreman, Lourens T Bloem, Stijn van Oirschot, Jarno Hoekman, Menno E van der Elst, Hubert Gm Leufkens, Olaf H Klungel, Wim G Goettsch, Aukje K Mantel-Teeuwisse
The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. International journal of health policy and management (2020)